ipilimumab,nivolumab,
bms,delcath systems
['chopin']
positive initial results from chopin phase 1b trial, focus trial update and qol study presented at the 2022 asco annua.. $dcth 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice